ORIC Pharma Collaborates With Pfizer For Phase 2 Study Of ORIC-533 In Multiple Myeloma; Stock Up

NEW YORK CITY (dpa-AFX) - ORIC Pharmaceuticals Inc. (ORIC) said that it has reached a clinical development collaboration with Pfizer for a potential phase 2 study of ORIC-533 in multiple myeloma.ORIC

Related Keywords

Jeff Settleman ,Pfizer ,Pharmaceuticals Inc ,Oncology Research Development ,Chief Scientific Officer ,Oncology Research ,Including Pfizer ,Foric ,Dharma ,Ollaborates ,Ith ,Hase ,Study ,Multiple ,Myeloma ,Stock ,